# Single Ascending Dose Study of HB2198 in Healthy Participants

> **NCT07439263** · PHASE1 · RECRUITING · sponsor: **Hinge Bio** · enrollment: 32 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody with Dual Fc Domains
- **DRUG:** Placebo comparator: HB2198 Diluent

## Key facts

- **NCT ID:** NCT07439263
- **Lead sponsor:** Hinge Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2026-08-14
- **Final completion:** 2026-08-21
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07439263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07439263, "Single Ascending Dose Study of HB2198 in Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07439263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*